No significant reduction in risk for major cardiovascular events seen in intention-to-treat analysis<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
MONDAY, Nov. 10, 2025 (HealthDay News) — For patients with acute coronary syndrome, targeted vitamin D3<\/sub> supplementation is associated with a reduced risk for follow-up myocardial infarction, according to a study presented at the American Heart Association Scientific Sessions 2025, held from Nov. 7 to 10 in New Orleans.<\/p>\n Heidi T. May, Ph.D., from Intermountain Health in Salt Lake City, and colleagues conducted a randomized trial involving 630 patients with acute coronary syndrome who were randomly assigned to receive standard of care or clinical management of 25-hydroxyvitamin D (25[OH]D) levels, with targeted supplementation reaching a target of >40 ng\/mL (316 and 314 patients, respectively).<\/p>\n The researchers found that 58.8 percent of patients randomly assigned to the treatment arm with a 25(OH)D level \u226440 ng\/mL began vitamin D3<\/sub> dosing at 5,000 IU. In the intention-to-treat analysis, there was no significant difference seen in the primary end point of major adverse cardiovascular events between the groups, but there was a significant reduction in follow-up myocardial infarction in the vitamin D3<\/sub> arm (3.8 versus 7.9 percent).<\/p>\n “Previous studies just gave patients supplementation without regularly checking blood levels of vitamin D to determine what supplementation achieved,” May said in a statement. “With more targeted treatment, when we checked exactly how supplementation was working and made adjustments, we found that patients had their risk of another heart attack cut in half.”<\/p>\n